Accessibility Menu
InnoCan Pharma logo

InnoCan Pharma

(OTC) INNPF

Current Price$2.48
Market Cap$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-80%
5 Year-92%
1 Year-74%
1 Month+3%
InnoCan Pharma last closing stock price
MetricPriceDate
Last closeUSD 2.482026-07-14
InnoCan Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+55%USD 1.602026-07-06
1 month+3.33%USD 2.402026-06-11
3 month-44.39%USD 4.462026-04-13
Year to date-65.7%USD 7.232025-12-30
1 year-73.5%USD 9.362025-07-08
3 year-80.31%USD 12.602023-06-22
5 year-91.81%USD 30.282021-07-13
Since inception-80.2%USD 12.532020-11-27

InnoCan Pharma Financials at a Glance

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$25.19M

Net Income (TTM)

-$1.50M

EPS (TTM)

-$0.34

P/E Ratio

-7.37

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Price

$2.48

Volume

100

Open

$2.48

Previous Close

$2.48

Daily Range

$2.48 - $2.48

52-Week Range

$0.13 - $14.26

Estimated Earnings Date

May 27, 2026

INNPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InnoCan Pharma

INNOCAN PHARMA Corp is a pharmaceutical company focused on developing innovative drug delivery systems that integrate cannabidiol (CBD) with various pharmaceutical ingredients. The company operates in multiple international markets, including the United States and Europe, and is dedicated to advancing research in CBD applications for health and wellness.

Products and Services
  • CBD-loaded exosomes for treating conditions like COVID-19
  • CBD-infused liposomes for enhanced drug delivery
  • Branded topical treatments, including CBD eye serum and recovery lotion
Growth Outlook
  • Recent quarterly revenue increased to $6.38 million, up from $5.06 million
  • Gross profit margin improved to 91.1% in Q1 2026
  • Strong cash position with $6.7 million in cash and cash equivalents
Financial Highlights
  • Trailing twelve months (TTM) revenue of $25.5 million
  • Operating cash flow of $368,000 in Q1 2025
  • Current ratio of 5.24 indicates strong liquidity
INNOCAN PHARMA Corp is positioned in the growing CBD market, leveraging innovative technologies to enhance drug delivery. The recent increase in quarterly revenue and improvement in gross profit margin reflect the company's potential for growth. With a solid cash position, INNOCAN is well-equipped to continue its research and development efforts, aiming to capitalize on the expanding demand for CBD-based products. The company's focus on innovative solutions in the pharmaceutical sector may attract interest from investors looking for opportunities in the healthcare industry.
AI Generated • Jul 13, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9

CEO

Iris Or Gabi Bincovich

Website

www.innocanpharma.com

Headquarters

Calgary, AB T2P 0N7, CA

INNPF Financials

Key Financial Metrics (TTM)

Gross Margin

89.81%

Operating Margin

-10.00%

Net Income Margin

-5.95%

Return on Equity

-31.76%

Return on Capital

-19.22%

Return on Assets

-13.80%

Earnings Yield

-13.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.50M

Volume

100

Avg. Volume

72.339

Financials (TTM)

Gross Profit

$22.62M

Operating Income

-$2.52M

EBITDA

-$683.22K

Operating Cash Flow

-$371.99K

Capital Expenditure

-$11.00K

Free Cash Flow

-$382.99K

Cash & ST Invst.

$6.70M

Total Debt

$1.42M

InnoCan Pharma Performance Analysis

InnoCan Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,559,0001205.6%
20232023-12-31USD 13,657,000433.7%
20242024-12-31USD 29,437,000115.5%
20252025-12-31USD 26,612,000-9.6%
InnoCan Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.1%
Q32025-09-30-3.7%
Q42025-12-31-24.9%
Q12026-03-3125.9%
InnoCan Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.98-66.2%
20232023-12-31USD -1.1921.0%
20242024-12-31USD -0.43-64.2%
20252025-12-31USD -0.25-41.0%
InnoCan Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-230.8%
Q42025-12-31202.3%
Q12026-03-31-147.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$6.38M

-18.2%

Gross Profit

$5.81M

-18.4%

Gross Margin

91.11%

N/A

Market Cap

$11.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.01M

N/A

Employees

11

N/A

Net Income

-$958.54K

-64.7%

EBITDA

-$767.22K

-1767.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.70M

+5.2%

Total Debt

$1.42M

+9.3%

Accounts Receivable

$1.31M

+20.4%

Inventory

$2.19M

-26.0%

Long Term Debt

$969.18K

-25.6%

Short Term Debt

$453.49K

+6378.4%

Return on Assets

-13.80%

N/A

Return on Invested Capital

-28.28%

N/A

Free Cash Flow

-$498.99K

-237.5%

Operating Cash Flow

-$498.99K

-235.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HITCHealthcare Integrated Technologies, Inc.
$0.30+0.00%
RTGNRetinalGenix Technologies Inc.
$4.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%

Questions About INNPF

What is the current price of InnoCan Pharma?

InnoCan Pharma is trading at $2.48 per share.

What is the 52-week range for InnoCan Pharma?

Over the past 52 weeks, InnoCan Pharma has traded between $0.13 and $14.26.

How much debt does InnoCan Pharma have?

As of the most recent reporting period, InnoCan Pharma reported total debt of $1.42M.

How much cash does InnoCan Pharma have on hand?

InnoCan Pharma reported $6.67M in cash and cash equivalents in its most recent financial results.

What is InnoCan Pharma’s dividend yield?

InnoCan Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services